your market intelligence analyst
Search Results
9 results
Your search is now limited to «Bristol-Myers Squibb» expert search.
Your search is now limited to only one Source. To return to results from all sources click here.
ENDPOINTS 09/27/2019 14:29
BARCELONA — Bristol-Myers Squibb’s Opdivo couldn’t quite beat Nexavar, the standard of care in hepatocellular carcinoma, in its Phase III head-to-head. But investigators are still hoping that it can play a role in the frontline setting of this disease. Thomas Yau of the University of Hong Kong, who led the study, hit hard on Opdivo’s “clinically meaningful” advantages over the entrenched therapy, particularly in terms of side effects and quality of life. Thomas Yau. Presenting at the 2019 Congress of the European Society of Medical Oncology, Yau readily conceded that the difference in overall survival — 16.4 months on Opdivo and 14.7 months for Nexavar — did not meet statistical significance (p=0.075). Yet he also suggested that the availabi.
ENDPOINTS 08/28/2019 10:03
Less than a year after the FDA cleared Bristol-Myers Squibb and AbbVie’s approved Empliciti injection for intravenous use in combination with Celgene’s pomalidomide (Pomalyst, or Imnovid, depending on which side of the Atlantic you are) and the steroid dexamethasone for relapsed, refractory multiple myeloma, the European Commission . The approval is based on data from the 117 patient-ELOQUENT-3 trial in which the triplet doubled both median progression-free survival (PFS) and overall response rate (ORR) among patients with relapsed and refractory multiple myeloma, versus pomalidomide and low-dose dexamethasone alone. Updated trial data — with a minimum follow-up of 18.3 months — were presented at the European Hematology Association (EHA) th.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications